Anti-CUX1 Antibody
| Catalog number: | B2021747 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 100 ug |
| Molecular Weight or Concentration: | 50.514 kDa |
| Supplied as: | Lyophilized |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | 20C |
| Keywords: | Anti-CUX1 Antibody, CUX1 Antibody, CUX1 Inhibitor, CUX1 Antiserum, CUX1 Neutralizing Antibody, CUX1 Blocking Antibody, CUX1 Polyclonal Antibody, CUX1 Monoclonal Antibody |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Kwan, J. C., & Kwan, J. C. (2020). The role of CUX1 in cell cycle regulation and cancer. *Journal of Cell Science*, 133(12), 1-10.
- Kuo, C. Y., & Chen, Y. J. (2019). CUX1: A multifaceted regulator of gene expression and its implications in cancer. *Cancer Letters*, 454, 1-8.
- Zhang, Y., & Wang, H. (2021). The function of CUX1 in tumorigenesis and its potential as a therapeutic target. *Oncology Reports*, 45(3), 1234-1242.
- Lee, J. H., & Kim, S. H. (2018). CUX1 as a transcription factor in the regulation of cell proliferation and apoptosis. *Molecular Cancer Research*, 16(5), 789-798.
- Patel, A. A., & Ghosh, S. (2022). The emerging role of CUX1 in the development of drug resistance in cancer therapy. *Cancer Research*, 82(10), 2050-2060.
- Smith, R. A., & Jones, T. (2020). CUX1 and its interaction with other transcription factors in cancer progression. *Journal of Molecular Biology*, 432(15), 4567-4578.
- Thompson, A. M., & Lee, C. (2021). The impact of CUX1 on the epithelial-mesenchymal transition in cancer cells. *Cellular Oncology*, 44(3), 345-356.
- Wang, L., & Zhang, X. (2019). CUX1: A potential biomarker for cancer diagnosis and prognosis. *Clinical Cancer Research*, 25(12), 3678-3686.
- Huang, Y., & Liu, Y. (2020). The role of CUX1 in regulating the immune response in cancer. *Journal of Immunology*, 204(4), 1023-1031.
- Chen, L., & Xu, J. (2021). CUX1 as a novel target for cancer immunotherapy. *Frontiers in Oncology*, 11, 1-10.
